Clinical Issues in Rheumatoid Arthritis
Debates & Discussions on the Evolving Role of JAK Inhibitors
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.
Schwartz DM, et al. Nat Rev Drug Discov. 2017;17(1):78.
Clinical efficacy of new JAK inhibitors under development. Just more of the same?
Westhovens R. Rheumatology (Oxford). 2019;58(suppl 1):i27-i33.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomized controlled trial.
Fleischmann R, et al. Lancet. 2017;390(10093):457-468.
Baricitinib versus placebo or adalimumab in rheumatoid arthritis.
Taylor PC, et al. N Engl J Med. 2017;376(7):652-662.
Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease‐modifying antirheumatic drug treatment.
Fleischmann R, et al. Arthritis Rheumatol. 2017;69(3):506-517.
A phase 3, randomized, controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis.
van Vollenhoven R, et al. Arthritis Rheumatol. 2018;70(suppl 10). Abstract 891.
A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate.
Fleischmann R, et al. Arthritis Rheumatol. 2018;70 (suppl 10). Abstract 890.
Safety and efficacy of filgotinib in a phase 3 trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic DMARDs.
Genovese MC, et al. Arthritis Rheumatol. 2018;70(suppl 10). Abstract L06.
Thromboembolism with Janus kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk?
Scott IC, et al. Drug Saf. 2018;41(7):645-653.
Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis.
Clowse ME, et al. Drug Saf. 2016;39(8):755-762.
Additional abstracts from the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting.
October 2018; Chicago, IL.
Guidelines
2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis.
Singh JA, et al. Arthritis Rheumatol. 2016;68(1):1-26.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Smolen JS, et al. Ann Rheum Dis. 2017;76(6):960-977.
Patient, Caregiver, and Provider Resources
American College of Rheumatology: Patient and Caregiver Resources
The ACR has produced a library of videos about the impact of rheumatic disease, what to do when diagnosed with rheumatic disease, when to see a rheumatologist, and what patients have to say about their experiences of living with rheumatic disease.
Arthritis Foundation
The Arthritis Foundation provides self-care tools and resources covering treatment options, pain management, diet and exercise, and common comorbidities associated with many different arthritic conditions.
European League Against Rheumatism
EULAR is an organization that represents people with arthritis/rheumatism, health professionals, and scientific societies of rheumatology of all the European nations.
NIH Health Topics: Rheumatoid Arthritis
A resource from the National Institute of Arthritis and Musculoskeletal and Skin Diseases for people who have rheumatoid arthritis, as well as for their family members, friends, and others who want to find out more about rheumatoid arthritis.
Clinical Issues in Rheumatoid Arthritis
Debates & Discussions on the Evolving Role of JAK Inhibitors
| Faculty: | Joel Kremer, MD, FACP, MACR (Moderator); Roy Fleischmann, MD, MACR; Maria Greenwald, MD, FACR |
| Release: | 07/19/2019 |
| Expiration: | 07/19/2020 |
